Roth Capital Reiterates Buy On Sarepta Therapeutics, Sees 31% Upside
In a research report published Monday, Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) with a price target of $22, which represents a potential upside of 31% from where the stock is currently trading.
Chattopadhyay noted, “With an NDA submission during mid-2015, accelerated approval (AA) may hinge upon: (1) independent rescoring of dystrophin positive fibers (currently underway) and (2) outcome of the fourth biopsy performed in conjunction with the 168 week 6MWT. Importantly, agreement with the FDA on a master protocol allows for two other exon skipping therapies to be evaluated simultaneously (study start 1H15), and potentially lays the groundwork for future class approval, in our view.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Debjit Chattopadhyay has a total average return of -0.7% and a 52.2% success rate. Chattopadhyay has a -13.4% average return when recommending SRPT, and is ranked #2627 out of 3388 analysts.